Joint FDA/FTC Warning Letter Concerning Product Labeling of Human Chrorionic Gonadotropin (HCG) Drugs
Date
By
Mary K. Engle, Associate Director
The FTC’s five Commissioners issue statements on a range of important topics to engage with the public and express the views of the Commission as well as their own individual views.
Displaying 801 - 820 of 1039
Statement of Commissioners Leibowitz, Kovacic, and Ramirez, In the Matter of Laboratory Corporation of America and Laboratory Corporation of America Holdings
Date
By
Matter Number
101 0152
Docket Number
9345
Concurring Statement of Commissioner Brill, In the Matter of Laboratory Corporation of America and Laboratory Corporation of America Holdings
Date
By
Julie Brill, Former Commissioner
Matter Number
101 0152
Docket Number
9345
Preliminary FTC Staff Privacy Report
Date
By
Jon Leibowitz, Former Chairman
File
Preliminary FTC Staff Privacy Report
(15.19 KB)
Statement of the Commission, In the Matter of Laboratory Corporation of America and Laboratory Corporation of America Holdings
Date
Matter Number
101 0152
Docket Number
9345
Dissenting Statement of Commissioner Rosch, In the Matter of Laboratory Corporation of America and Laboratory Corporation of America Holdings
Date
By
J. Thomas Rosch, Former Commissioner
Matter Number
101 0152
Docket Number
9345
Statement of Chairman Leibowitz on the Release of the 2010 Horizontal Merger Guidelines
Date
By
Jon Leibowitz, Former Chairman
Matter Number
P092900
Horizontal Merger Guidelines of the United States Department of Justice and the Federal Trade Commission
Concurring Statement of Commissioner Julie Brill
Date
By
Julie Brill, Former Commissioner
Matter Number
P094806
Concurring Statement of Commissioner Julie Brill and Chairman Jon Leibowitz
Date
By
Jon Leibowitz, Former Chairman;
Julie Brill, Former Commissioner
Docket Number
C-4262
Statement of Chairman Leibowitz and Commissioner Rosch, In the Matter of Intel Corporation
Date
By
Jon Leibowitz, Former Chairman;
J. Thomas Rosch, Former Commissioner
Matter Number
061 0247
Docket Number
9341
Concurring and Dissenting Statement of Commissioner Rosch, In the Matter of Intel Corporation
Date
By
J. Thomas Rosch, Former Commissioner
Matter Number
061 0247
Docket Number
9341
Statement of FTC Chairman Jon Leibowitz Senate Judiciary Committee's Passage of the Preserve Access to Affordable Generics Act (S. 369)
Date
By
Jon Leibowitz, Former Chairman
By taking this action, the Committee clearly recognizes the very real danger that these sweetheart deals pose to Americans struggling to pay their medical bills. Consumers must wait – sometimes years...
Statement of FTC Chairman Jon Leibowitz Regarding the Announcement that Arthur D. Levinson Has Resigned from Google's Board
Date
By
Jon Leibowitz, Former Chairman
On October 12, 2009, Google announced that Arthur D. Levinson, the former Chief Executive Officer of Genentech and a member of the corporate boards of both Google and Apple, is stepping down from...
Concurring Statement of Commissioner Harbour, In the Matter of Aspen Technology, Inc
Date
By
Pamela Jones Harbour, Former Commissioner
Matter Number
021 0153
Docket Number
9310
Displaying 801 - 820 of 1039